Teva’s bid to combine with the generic-drug business of Allergan would vault the Israeli company into the top ranks of global drug makers and further a remodeling of the industry by a few players that were relatively unknown just a few years ago.
from WSJ.com: US Business http://ift.tt/1KstE7E
via IFTTT
No comments:
Post a Comment